Testing a new advanced prostate cancer medication for safety

Plain-English translation of NCT06705686 on ClinicalTrials.gov ↗ · Source last updated March 2026 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

This is one of the first times this treatment has been tested in people.

What is this trial?

This is the first human trial of a new medication called (R)-9b, which is designed to target a specific protein that helps prostate cancer grow. The trial will test whether the medication is safe to take and what dose works best in men with advanced prostate cancer that has stopped responding to other hormonal treatments. Researchers will also look for early signs that the medication might help control the cancer.

Men with advanced prostate cancer that no longer responds to standard hormonal therapies have very few treatment options. This medication was developed because laboratory studies show it may work differently than existing treatments and could help even when other drugs have stopped working.

Do you qualify?

You likely qualify if…

you have been diagnosed with metastatic castration-resistant prostate cancer (prostate cancer that has spread and stopped responding to hormone therapy)
you have evidence of cancer spread on imaging scans (such as bone, lymph node, or other organ involvement)
you have had your testosterone levels reduced to castrate levels through medication or surgery and are maintaining those levels
your prostate cancer has continued to progress despite treatment with at least one modern hormonal therapy drug
your blood counts, liver function, and kidney function are normal or near-normal
you are able to understand the study and willing to sign the consent form

You likely don't qualify if…

you have not received prior treatment with modern hormonal therapy drugs for your prostate cancer
your blood counts, liver function, or kidney function are significantly abnormal
you have received radiation therapy within the last 2–4 weeks
you are not maintaining castrate testosterone levels through ongoing hormone therapy or surgery

What participation looks like

You would take the medication by mouth twice daily (every 12 hours) for up to 6 months, with each treatment cycle lasting 28 days. The trial has two phases: first, a dose-escalation phase where doctors gradually increase your dose to find the safest level, then an expansion phase where more patients take the dose determined to be safest. During the study, you would have regular visits for blood tests, imaging scans to check your cancer, and biopsies to help researchers understand how the medication is working.

AI-generated summary from trial data · Jun 18, 2026 · Not medical advice

Trial locations(1 site)

United States

University of Wisconsin Carbone Cancer Center (UWCCC) - Cancer Connect, Madison, Wisconsin

Key details

Phase

Safety & dosing

Sponsor

TechnoGenesys, Inc.

Collaborators

National Cancer Institute (NCI), Washington University School of Medicine

Enrollment target

~40 participants

Started

March 2026

Primary completion

December 2027

Age range

18 Years and older

Sex

Male only

Last updated on clinicaltrials.gov in March 2026.

Contact the research team directly

Reach out to the team running this trial. Response times vary — some teams are faster than others.

Central contact

Nupam Mahajan, PhD

University of Wisconsin, Madison

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.

View full record on ClinicalTrials.gov